This guideline includes statements and recommendations based on available, high-level evidence about the use of bisphosphonates for advanced breast cancer. The guideline provides health professionals with information designed to help them make management recommendations for improved patient outcomes. NBOCC* also develops information specifically for consumers about the diagnosis and treatment of advanced breast cancer.
A clinical practice guideline developed by (NBOCC)*
This document supplements guideline recommendation 27 on the use of bisphosphonates as supportive treatment (page 10) and guideline recommendation 47 on bisphosphonates as analgesics for cancer pain (page 12) contained in the National Breast Cancer Centre (NBCC)* Clinical practice guidelines for the management of advanced breast cancer, 2001.1
Incorporates published evidence to October 2010
- The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
- Medical Oncology Group of Australia Inc. (MOGA)
© Cancer Australia 2011
* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
|Guideline Topic||Advanced Breast Cancer|
|Cancer Types||Breast cancer|
This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.